Klingenstein Fields & Co Portfolio holdings
Klingenstein Fields & Co., which does business as Klingenstein Fields Advisors, is an independently owned wealth manager for high net worth individuals, families, foundations and nonprofits. Its roots lie in Wertheim & Company, a merchant bank started by Joseph Klingenstein and Maurice Wertheim, which later joined with Schroder as Wertheim Schroder. Frederick Klingenstein, who had led Wertheim's expansion into investment banking and investment management, left Wertheim Schroder with John Klingenstein and Ken Fields to form Klingenstein Fields. It provides wealth planning and investment management built around each client's goals.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$5.23M |
| 2 |
Eli Lilly
LLY
|
+$431K |
| 3 |
Abbott
ABT
|
+$312K |
| 4 |
Exelixis
EXEL
|
+$227K |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$226K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab International Equity ETF
SCHF
|
+$15.5M |
| 2 |
Schwab Emerging Markets Equity ETF
SCHE
|
+$14M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$11.5M |
| 4 |
Broadcom
AVGO
|
+$8.48M |
| 5 |
Schwab U.S Small- Cap ETF
SCHA
|
+$3.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.97% |
| 2 | Financials | 13.87% |
| 3 | Healthcare | 11.95% |
| 4 | Communication Services | 10.39% |
| 5 | Industrials | 8.83% |
Similar funds
Klingenstein Fields & Co's Q4 2024 Portfolio in Review
As of Q4 2024, Klingenstein Fields & Co held 187 positions worth $2.48B, down 1.4% from $2.52B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Klingenstein Fields & Co's Q4 2024 filing shows 3 new, 37 increased, 75 reduced and 7 closed positions. Its largest new stake was Exelixis: 7,000 shares worth $233K. The largest sale was Schwab International Equity ETF, an estimated $15.5M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Financials and Healthcare.
- Klingenstein Fields & Co's largest Q4 2024 buy was Exelixis: 7,000 shares worth $233K.
- Klingenstein Fields & Co added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $5.23M increase.
- Klingenstein Fields & Co's biggest Q4 2024 reduction was Schwab International Equity ETF, cutting an estimated $15.5M.
- Klingenstein Fields & Co fully exited First Trust Long/Short Equity ETF in Q4 2024, selling an estimated $2.04M.
- Klingenstein Fields & Co's ten largest holdings make up 37% of its $2.48B portfolio in Q4 2024.
- Klingenstein Fields & Co opened 3 new positions and closed 7 in Q4 2024.
- Klingenstein Fields & Co's portfolio value fell 1.4% quarter-over-quarter to $2.48B.
Based on Klingenstein Fields & Co's 13F filing for Q4 2024, filed 30 Jan 2025.